Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by Jesus4Prezon Oct 27, 2020 4:37pm
302 Views
Post# 31790279

Staged Buyout

Staged BuyoutWould anyone agree with this thought:   Don's Option 1 Development Plan sounds very much like a Contingent Value Rights deal, essentially a staged buyout with a floor price in place and room for extra based on milestones.  If so, I would expect zero dilution from the deal.  In fact I would imagine the upfront could be quite large, even to the extent the company could start buying back some shares if the price dips again in the future, causing consolidation of share value, not dilution.  Also, I wonder if it could be a buyout that dissolves existing shares at a nice PPS, plus creating some new shares (non-voting) for potential future milestone payments.  Dare to dream.  Thoughts anyone?

Also, I seem to remember a time maybe 5 years ago, when in one presentation it was suggested the future total revenue of the company could be 150 billion.  A short time later I also heard the number 350 billion.  Does anybody else remember those numbers being thrown around at an investor presentation in the past?

Without a doubt the indications we are working in are huge.  To me a buyout of this cutting edge technology makes all the sense in the world, especially if two SGLT2 manufacturers each want the role of 'partner'.

J4P
<< Previous
Bullboard Posts
Next >>